Wall St Engine
@wallstengine
Fast, accurate, consistent stock market news, earnings highlights & more. By Brillinsight. Not financial advice.
Joined March 2022
996 Following 214.4K Followers
Novo $NVO says CagriSema delivered superior weight loss against Lilly's $LLY tirzepatide in the REIMAGINE 5 trial. At the 1.0 mg dose of each component, patients lost 12.4% of body weight at week 60, against 9.1% on tirzepatide.
Show more
